{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:09:45Z","timestamp":1782580185590,"version":"3.54.5"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Diabetes Mellitus (DM) represents a global health crisis, currently affecting approximately 9% of the world\u2019s population. Its prevalence continues to rise steadily, with a noticeable trend toward onset at younger ages. Projections indicate that the prevalence will reach 12% by 2045 equivalent to 820 million cases\u2014positioning DM as one of the most serious public health threats worldwide. Pathogenetically, DM is classified into Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM), with T2DM accounting for over 90% of all cases. T2DM is characterized by pancreatic \u03b2-cell dysfunction and insulin resistance, and is recognized as a multisystem metabolic disorder involving pathways such as the gut-brain axis, insulin\/peripheral resistance, etc strongly correlated with obesity and cardiovascular diseases. Recent advances in basic medical research and clinical therapeutics have optimized the application of glucagon-like peptide-1 (GLP-1), establishing it as a cornerstone incretin based therapy for T2DM management. In parallel, metabolic surgery has demonstrated significant potential in ameliorating symptoms of T2DM. This article comprehensively reviews current trends in T2DM treatment, the molecular profile of GLP-1, biological characteristics of GLP-1-secreting L-cells, the development of GLP-1-related pharmaceuticals, and advances in metabolic surgery (MS). We searched the primary literature in PubMed, Embase and SciELO from inception to June 2025, using the terms \u201cdiabetes\u201d, \u201ctype 2 diabetes mellitus\u201d, \u201cglucagon-like peptide-1\u201d, \u201cL-cell\u201d, \u201cmetabolic surgery\u201d, \u201cjejunostomy\u201d, \u201cGLP-1 receptor agonists\u201d as well as their combinations. We included basic\/mechanistic studies, human observational studies, randomized clinical trials and observational\n                    <jats:italic>post hoc<\/jats:italic>\n                    analyses of trials that were relevant to the review topic. The aim is to provide insights and references for future strategies in personalized precision medicine for T2DM.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2025.1721842","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:24:26Z","timestamp":1767612266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Research progress in precision medicine for type 2 diabetes based on the GLP-1"],"prefix":"10.3389","volume":"16","author":[{"given":"Sangui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenrong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanlei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.24875\/ACME.M23000372","article-title":"Prevalence of diabetes, epidemiological characteristics and vascular complications","volume":"93","author":"Russo","year":"2023","journal-title":"Arch Cardiol Mex"},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.102","article-title":"Diabetes and its comorbidities\u2013where East meets West","volume":"9","author":"Kong","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031882","article-title":"The role of obesity in type 2 diabetes mellitus-an overview","volume":"25","author":"Chandrasekaran","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S003","article-title":"Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"111717","DOI":"10.1016\/j.diabres.2024.111717","article-title":"Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison","volume":"212","author":"Osumili","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/BF00274797","article-title":"Pancreatic and intestinal processing of proglucagon in man","volume":"30","author":"Orskov","year":"1987","journal-title":"Diabetologia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: Molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.97854","article-title":"Mechano-regulation of GLP-1 production by Piezo1 in intestinal L cells","volume":"13","author":"Huang","year":"2024","journal-title":"Elife"},{"key":"B17","doi-asserted-by":"publisher","first-page":"694284","DOI":"10.3389\/fendo.2021.694284","article-title":"What is an L-cell and how do we study the secretory mechanisms of the L-cell","volume":"12","author":"Kuhre","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(83)90146-4","article-title":"Tissue localization and relative distribution of regulatory peptides in separated layers from the human bowel","volume":"84","author":"Ferri","year":"1983","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"105283","DOI":"10.1016\/j.ebiom.2024.105283","article-title":"Regulator of G-protein signaling expression in human intestinal enteroendocrine cells and potential role in satiety hormone secretion in health and obesity","volume":"107","author":"Mcrae","year":"2024","journal-title":"EBioMedicine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature24489","article-title":"A single-cell survey of the small intestinal epithelium","volume":"551","author":"Haber","year":"2017","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.cell.2018.08.063","article-title":"Spatial reconstruction of single enterocytes uncovers broad zonation along the intestinal villus axis","volume":"175","author":"Moor","year":"2018","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.07.014","article-title":"Single-cell RNA-sequencing reveals a distinct population of proglucagon-expressing cells specific to the mouse upper small intestine","volume":"6","author":"Glass","year":"2017","journal-title":"Mol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.cell.2018.12.029","article-title":"Identification of enteroendocrine regulators by real-time single-cell differentiation mapping","volume":"176","author":"Gehart","year":"2019","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"102907","DOI":"10.1016\/j.dsx.2023.102907","article-title":"Colonic L-cell impairment in aged subjects with type 2 diabetes leads to diminished GLP-1 production","volume":"17","author":"Wang","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110179","DOI":"10.1016\/j.celrep.2021.110179","article-title":"Intestinal Gpr17 deficiency improves glucose metabolism by promoting GLP-1 secretion","volume":"38","author":"Yan","year":"2022","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl1460","article-title":"Description and functional validation of human enteroendocrine cell sensors","volume":"386","author":"Beumer","year":"2024","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"240303","DOI":"10.1098\/rsob.240303","article-title":"GLP-1\/GLP-1R axis: from metabolism (obesity and T2DM) to immunity","volume":"15","author":"Kumar","year":"2025","journal-title":"Open Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"170749","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides"},{"key":"B30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/13543784.2023.2283020","article-title":"Retatrutide showing promise in obesity (and type 2 diabetes)","volume":"32","author":"Doggrell","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae128","article-title":"GLP-1, GIP, and glucagon agonists for obesity treatment: A hunger perspective","volume":"165","author":"D\u2019\u00e1vila","year":"2024","journal-title":"Endocrinology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/00000658-199206000-00010","article-title":"Is type II diabetes mellitus (NIDDM) a surgical disease","volume":"215","author":"Pories","year":"1992","journal-title":"Ann Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0762","article-title":"The effect of standard versus longer intestinal bypass on GLP-1 regulation and glucose metabolism in patients with type 2 diabetes undergoing roux-en-Y gastric bypass: the long-limb study","volume":"44","author":"Miras","year":"2021","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11695-012-0802-1","article-title":"A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass","volume":"23","author":"Arterburn","year":"2013","journal-title":"Obes Surg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001509","article-title":"Gastric bypass surgery leads to long-term remission or improvement of type 2 diabetes and significant decrease of microvascular and macrovascular complications","volume":"263","author":"Chen","year":"2016","journal-title":"Ann Surg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-007-9053-y","article-title":"Vertical gastric resection (sleeve gastrectomy) in a morbidly obese patient with past jejunoileal bypass","volume":"17","author":"Lutrzykowski","year":"2007","journal-title":"Obes Surg"},{"key":"B38","doi-asserted-by":"publisher","first-page":"99526","DOI":"10.4239\/wjd.v16.i1.99526","article-title":"Clinical study on the effect of jejunoileal side-to-side anastomosis on metabolic parameters in patients with type 2 diabetes","volume":"16","author":"Wang","year":"2025","journal-title":"World J Diabetes"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/0973-1482.191618","article-title":"Laparoscopic jejunoileal side-to-side anastomosis for the treatment of type 2 diabetes mellitus in Chinese patients with a body mass index of 24\u201332 kg\/m(2)","volume":"12","author":"Li","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"103447","DOI":"10.4239\/wjd.v16.i5.103447","article-title":"Jejunoileal side-to-side anastomosis: New hope for patients with type 2 diabetes","volume":"16","author":"Shao","year":"2025","journal-title":"World J Diabetes"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41598-021-84355-x","article-title":"The role of gut microbiota and amino metabolism in the effects of improvement of islet \u03b2-cell function after modified jejunoileal bypass","volume":"11","author":"Tan","year":"2021","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2525335","DOI":"10.1080\/08941939.2025.2525335","article-title":"Optimized minimally invasive jejunoileal bypass compared to traditional minimally invasive jejunoileal bypass in the treatment of type 2 diabetes: A retrospective cohort study","volume":"38","author":"Chen","year":"2025","journal-title":"J Invest Surg"},{"key":"B43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13098-023-01001-4","article-title":"Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis","volume":"15","author":"Mirghani","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.14392","article-title":"New molecules and indications for GLP-1 medicines","volume":"334","author":"Gonzalez-Rellan","year":"2025","journal-title":"Jama"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2015.02.011","article-title":"Detailed characterization of incretin cell distribution along the human small intestine","volume":"11","author":"Guedes","year":"2015","journal-title":"Surg Obes Relat Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.27062","article-title":"Differential GIP\/GLP-1 intestinal cell distribution in diabetics\u2019 yields distinctive rearrangements depending on Roux-en-Y biliopancreatic limb length","volume":"119","author":"Palha","year":"2018","journal-title":"J Cell Biochem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.cmet.2020.04.005","article-title":"Patch-seq links single-cell transcriptomes to human islet dysfunction in diabetes","volume":"31","author":"Camunas-Soler","year":"2020","journal-title":"Cell Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1101\/gr.212720.116","article-title":"Single-cell transcriptomes identify human islet cell signatures and reveal cell-type-specific expression changes in type 2 diabetes","volume":"27","author":"Lawlor","year":"2017","journal-title":"Genome Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.934775","article-title":"Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion","volume":"13","author":"Holter","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1590\/0102-672020220002e1681","article-title":"Small intestinal L cell density in patients with severe obesity after roux-en-Y gastric bypass","volume":"35","author":"Estabile","year":"2022","journal-title":"Arq Bras Cir Dig"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-024-01554-2","article-title":"Comparative effects of GLP-1 agonists, sleeve gastrectomy and roux-en-Y gastric bypass on diabetes mellitus outcomes","volume":"24","author":"Essop","year":"2024","journal-title":"Curr Diabetes Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28073094","article-title":"Obesity and type 2 diabetes: adiposopathy as a triggering factor and therapeutic options","volume":"28","author":"Artasensi","year":"2023","journal-title":"Molecules"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00757-5","article-title":"Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia","volume":"19","author":"Sandoval","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e89409","DOI":"10.7759\/cureus.89409","article-title":"Long-term efficacy of bariatric surgery compared to modern medical therapy in type 2 diabetes and obesity: A systematic review","volume":"17","author":"Afzal","year":"2025","journal-title":"Cureus"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e71684","DOI":"10.7759\/cureus.71684","article-title":"Comparative effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists on cardiovascular outcomes and mortality: A meta-analysis","volume":"16","author":"Saeed","year":"2024","journal-title":"Cureus"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.07.012","article-title":"Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies","volume":"36","author":"Morissette","year":"2025","journal-title":"Trends Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1721842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:24:26Z","timestamp":1767612266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1721842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":57,"alternative-id":["10.3389\/fendo.2025.1721842"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1721842","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1721842"}}